I'm not quite sure the sigificance of this to Zenith and ZEN-3694 and RVX-208 but I found this to be very interesting and a drug which has many similarities so I thought I would share this with the boards.

This morning on was on my Nordic Track wathching Fox News and they had a piece on ONT-380 - a small molecule selective inhibitor of HER2 ( in 2 Phase 1b trials and recruiting in a third trial in US) for treatment of Metastatic Breast Cancer. The drug is being developed by Arry Biopharma ARRY(Nasdaq) whom has partnered with AZ. The patient interviewed is a participant in one of the trials and has responded well to the treatment. Final results for the clinical trials are not due until 2018 or 2019. I checked the early trading after the piece was aired and ARRY is up over 7% with almost 700k shares traded.

I couldn't help but think where RVX and Zenith would be with some positive results and good press.

Chicagoest